

DAFTAR PUSTAKA

- Andayani, T. M. 2013, *Farmakoekonomi Prinsip dan Metodologi*, Bursa Ilmu, Yogyakarta.
- Bootman, J. L., Townsend, R. J. and McGhan, W. F. 2005, *Principles of Pharmacoeconomics*, 3rd ed, Harvey Whitney Book Company, USA.
- Bourdet, S.V. and Williams, D.M. 2005, Chronic Obstructive Pulmonary Disease, in Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke G.R., Wells, B.G., Posey, L.M., (Eds.), *Pharmacotherapy: A Pathophysiologic Approach*, Sixth Edition, McGraw-Hill Companies, USA, pp 537-554.
- Brashier, B.B. and Kodgule, R. 2012, Risk Factors and Pathophysiology of Chronic Obstructive Pulmonary Disease (COPD), *J Assoc Physicians India*, **60**: 17–21.
- Buist, A.S., McBurnie, M.A., Vollmer, W.M., Gillespie, S., Burney, P., Mannino, D.M., *et al.* 2007, International Variation in the Prevalence of COPD (the BOLD Study): a population-based prevalence study, *The Lancet*, **370**: 741–750.
- Calverley, M.A., Stockley, R.A., Seemungal, A.R., Hagan, G., Willits, L.R., Riley, J.H., *et al.* 2011, Reportes Pneumonia in Patients with COPD, *American College of Chest Physicians*, **139**: 505-512.
- Chan-Yeung, M., Ait-Khaled, N., White, N., Ip, M.S. and Tan, W.C. 2004, The Burden and Impact of COPD in Asia and Africa [State of the Art]. *Int. J. Tuberc. Lung Dis*, **8**: 2–14.
- Charlson, M.E., Pompei, P., and Ales, K.L. 1987, A New Metod of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation, *Journal Chronic Disease*, **40**: 549-555.
- Chen, C.S., Reilly, K.H., Gu, D.F., Duan, X.F. and Wu, X. 2008, Risk Factors for COPD Mortality in Chinese Adult. *Am Journal of Epidemiol*, **167**: 998-1004.
- Corrado, A., Renda, T. and Bertini, S. 2010, Long-Term Oxygen Therapy in COPD: Evidences and Open Questions of Current Indications. *Monaldi Arch Chest Dis*. **73**: 34-43.
- Charlson, M.E., Pompei, P. and Ales, K.L. 1987, A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation, *Journal Chronic Disease*, **40**: 373–383.

- Dipiro, J.T., Talbert, R.L., Yee, G.Y., Matzke, G.R., Wells, B.G. and Posey, L.M. 2008, *Pharmacotherapy: A Pathophysiologic Approach*, Seventh Ed., McGraw-Hill.
- Dirjen Binfar and Alkes. 2013, *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan RI, Jakarta.
- Dowling, R.B., Johnson, M., Cole, P.J. and Wilson, R. 1998, Effect of Salmeterol on Haemophilus Influenzae Infection of Respiratory Mucosa in Vitro, *Eur Respir J.*, **11**:86-90
- Emre, C.J., Ozdemir, O., Baysak, A., Aksoy, U., Ozdemir, P., Oz, A.T., et al. 2015, Clinical Factors Affecting the Costs of Hospitalized Chronic Obstructive Pulmonary Disease Exacerbations, *Eurasian J. Pulmonol*, **16**: 180–183.
- Foo, J., Landis, S.H., Maskell, J., Oh, Y.M., Van, M.T., Han, M.K., et al. 2016, Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries, *PloS One*, **11**: 1371-1386.
- GOLD. 2017, *Global Initiative for Chronic Obstructive Lung Disease*, Global Strategy Diagnosis Management Prevalence Chronic Obstructive Pulmonary Disease.
- Ikawati, Z. 2016, *Penatalaksanaan Terapi Penyakit Sistem Pernapasan*, Bursa Ilmu, Yogyakarta.
- Indreswari, Y.S., Rumende, C.M. and Pitoyo, C.W. 2014, Faktor-Faktor yang Berhubungan dengan Eksaserbasi pada Pasien Penyakit Paru Obstruktif Kronik di Rumah Sakit Cipto Mangunkusumo, Jakarta, *Indonesian Journal of Chest Critical and Emergency Medicine*, **1**: 160-164.
- Kallaru, H., Nagasubramanian, V.R., Balakrishnan, H.P., Gopal, K. and Palani, T. 2015, Impact of Severity of the Disease on Cost of Illness and Quality of Life of Patients with Chronic Obstructive Pulmonary Disease, *Journal of Young Pharmacists*, **7**:106-112.
- Kosen, S. 2008, Dampak Kesehatan dan Ekonomi Perilaku Merokok di Indonesia, *Buletin Penelitian Sistem Kesehatan*, **11**: 207–211.
- Kruti, D.P., Tarachand, L. and Kartik, S. 2014, Economic Burden in Direct Cost of Chronic Obstructive Pulmonary Disease at a Tertiary Care Teaching Hospital: A Prospective Observational Cohort Study, *Indian J. Pharm. Pract*, **7**: 61–68.

- Mannino, D.M., Higuchi, K., Yu, T.C., Zhou, H., Li, Y., Tian, H., *et al.* 2015, Economic Burden of COPD in the Presence of Comorbidities, *Chest*, **148**: 138–150.
- Mathers, C.D. and Loncar, D. 2006, Projections of global mortality and burden of disease from 2002 to 2030, *Plos Med*, **3**: 2011-2030.
- Mosenifar, Z. 2017, 'Chronic Obstructive Pulmonary Disease (COPD)', diakses pada 5 mei 2017, <<http://emedicine.medscape.com/article/297664-overview>>.
- Ong, Y.Y., Woo, K.T., Han S.N., Tan, P. and Ong T.T. 2005, *A Clinical Approach to Medicine*, Stallion Press, Singapore.
- Patel, J., Dalal, A. and Nagar, S. 2014. Indirect Costs in Chronic Obstructive Pulmonary Disease: a Review of the Economic Burden on Employers and Individuals in the United States, *Int. J. Chron. Obstruct. Pulmon. Dis*, **9**: 289-300.
- PDPI (Perhimpunan Dokter Paru Indonesia). 2011, *PPOK (Penyakit Paru Obstruktif Kronis) Diagnosis dan Penatalaksanaan*, Perhimpunan Dokter Paru Indonesia, Jakarta.
- Putri, F. 2009, 'Analisis Biaya Penyakit Paru Obstruksi Kronis Pasien Rawat Inap RSUD Dr. Moewardi Surakarta berdasarkan Jenis Pembiayaan Periode Tahun 2008', *Tesis*, MSc, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.
- Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P., *et al.* 2007, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary, *Am. J. Respir. Crit. Care Med*, **176**: 532–555.
- Rascati, K.L. 2009, *Essentials of Pharmacoeconomics*. Wolter Kluwer, Lippincott Williams and Wilkins, London.
- Riskesdas. 2013, *Riset Kesehatan Dasar*, Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Tan, W.C and Ng, T.P. 2008, COPD in Asia. *Chest*, **133**: 517–527.
- Torabipour, A., Hakim, A., Angali, K.A., Dolatshah, M. and Yusofzadeh, M. 2016, Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study, *Tanaffos* **15**: 75-82.

Vijayan, V.K, 2013, Chronic Obstructive Pulmonary Disease. *Indian J. Med Res*, **137**: 251–269.

Vogenberg, F.R. 2001, *Introduction to Applied Pharmacoeconomic*, Zollo S. McGraw-Hill Companies, USA.

Wacker, M.E., Jörres, R.A., Schulz, H., Heinrich, J., Karrasch, S., Karch, A., *et al.* 2016. Direct and Indirect Costs of COPD and its Comorbidities: Results from the German Cosyconet study. *Respir. Med.*, **111**: 39–46.

Wilson, J. P. and Rascati, K. L. 2001, *Pharmacoeconomic*, McGraw-Hill, New York.